TransCode Therapeutics Inc. (NASDAQ:RNAZ) jumped over 15% but was down 37% in the past month. The company has priced its initial public offering of 6.25 million common shares at an offering price of $4 per share. TransCode expects gross proceeds of $25 million before accounting for offering expenses and subtracting underwriting commissions and discounts. Equally, …
NASDAQ:RNAZ
TransCode Therapeutics Inc (NASDAQ:RNAZ) Stock Continues to Fall: Down 36% in a Week
The RNA oncology firm TransCode Therapeutics Inc (NASDAQ:RNAZ) has not had a great time in recent days as far as its stock performance is concerned. On Wednesday, the stock suffered from another selloff and went down by 16% to takes its losses for the week to 36%. Earlier on this week the company completed its …
TransCode Therapeutics (NASDAQ:RNAZ) Sees Heavy Selling pressure: Where is The Bottom?
TransCode Therapeutics (NASDAQ:RNAZ) dropped 29% after the upcoming RNA oncology company priced its initial public offering (IPO) of 6.25 million common shares at $4 per share. The company expects gross proceeds of around $25 million before accounting for offering expenses and underwriting commissions and discounts. Also, the company has given underwriters 45 days to acquire …